Expert Interview
Discussing ALX Oncology's CD47 blocker evorpacept (ALX148) in combination with azacitidine and venetoclax in patients with AML
Ticker(s): ALXOInstitution: Fred Hutchinson Cancer Center
- Professor, Clinical Research Division, at Fred Hutch & Director of the largest genome and transcriptome sequencing project in pediatric and young adult AML.
- Developed numerous clinical assays that have been implemented in cooperative group trials; Created a robust biorepository of viable cells, plasma and extracted nucleic acids from over 100,000 specimens from 3,000 patients.
- Expert in leukemia biology, peripheral blood stem cell transplantation for children with leukemia, management of post-transplant relapse and targeted therapies for acute myeloid leukemia patients.
Roughly how many patients with AML do you currently manage?
Added By: c_adminCould you talk a little bit about your professional background, and
some details about your clinical practice?
What are your thoughts on the approach of ALX148? And is this
differentiated at all in this space, in your view?
Would the combination run into the issue of depleting the immune system function?
Just to get a sense for the role of ven/aza currently
in the treatment of AML, could you talk about that?
If you had to rate your level of excitement about ALX148 on a
one to 10 scale, how would you rate that and why?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
